ALMS
Alumis Inc: Year-End 2025 Financial Results and Strategic TYK2 Pipeline Outlook
Executive Summary Alumis Inc., a late-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases, reported its financial…